Astellas Pharma Inc. (“Astellas Pharma”; Headquarters: Chuo-ku, Tokyo; President and CEO: Yoshihiko Hatanaka) and sanofi-aventis K.K. (“sanofi-aventis”; Headquarters: Shinjuku-ku, Tokyo; Representative Director and President: Jez Moulding) announced that Astellas Pharma will transfer the rights to distribute the injectable antibiotics Targocid® (generic name: teicoplanin) and the treatment for peptic ulcer and gastritis Maalox® (generic name: dried aluminum hydroxide gel and magnesium hydroxide) to sanofi-aventis effective on January 1, 2012. This transfer of distribution rights is taking place based on the expiration of the contract.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1,625 JPY | -3.99% | -1.31% | -3.62% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-3.62% | 20.05B | |
+33.46% | 701B | |
+26.24% | 571B | |
+0.93% | 381B | |
+21.03% | 334B | |
+17.51% | 319B | |
+0.74% | 210B | |
+2.95% | 210B | |
-6.05% | 201B | |
-3.61% | 157B |
- Stock
- Equities
- Stock Astellas Pharma Inc. - Japan Exchange
- News Astellas Pharma Inc.
- Astellas Pharma : Transfer of Distribution Rights for Targocid® and Maalox®